ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Neurana Announces Top-Line Results from Tolperisone Phase 1 CNS Effects Study
December 30, 2020Neurana Pharmaceuticals announced positive top-line results from the Phase 1 central nervous effects (CNS) clinical study of tolperisone. The study, utilizing a validated driving test, confirmed that tolperisone does not impair driving performance. -
Neurana Announces Completion of Tolperisone Phase 2 Study Enrollment
June 20, 2019Neurana Pharmaceuticals has completed enrollment in the "STAR Study," a Phase 2 dose ranging study of tolperisone in acute muscle spasms of the back in over 400 patients.
Pharma Sources Insight January 2025
